With $300 million in facility-specific investment and 120 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). This project also meets AFT's primary-source verification and physical U.S. manufacturing-footprint requirements.
View full methodology →The pharmaceuticals context.
Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.
At a glance
- Company
- BeOne Medicines
- Industry
- Pharmaceuticals
- Location
- Hopewell Township, New Jersey
- Investment
- $300.0M
- Permanent jobs announced
- 120
- Status
- Planning
- Announced
- Jul 23, 2026
- Expected opening
- 2029
- Added to tracker
- Aug 14, 2026
Official references
- New Jersey Economic Development Authority approval https://www.njeda.gov/oncology-therapies-manufacturer-approved-for-njeda-next-new-jersey-manufacturing-award/
- Company facility context https://beonemedicines.com/about/manufacturing/hopewell-manufacturing-site/
- Hopewell Township announcement https://www.hopewelltwp.org/m/newsflash/Home/Detail/1641
- Reuters corroboration https://www.reuters.com/world/beone-announces-300-million-expansion-us-manufacturing-facility-2026-07-23/